Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 415-421

  Chopra, Sidharth ^a   Matsuyama, Karen ^a   Tran, Tran ^a   Malerich, Jeremiah P ^a   Wan, Baojie ^b   Franzblau, Scott G ^b   Lun, Shichun ^c   Guo, Haidan ^c   Maiga, Mariama C ^c   Bishai, William R ^c,d,e   Madrid, Peter B ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Benzimidazole; Ciprofloxacin; Drug resistance; Non replicating bacteria; Non tuberculous mycobacteria; Novobiocin; Topoisomerase

Indexed keywords

AB 1; BENZIMIDAVIR; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ISONIAZID; NOVOBIOCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SCREENING; DRUG TARGETING; FEMALE; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SHAM PROCEDURE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; DNA GYRASE; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; LUNG; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NOVOBIOCIN; TUBERCULOSIS, PULMONARY;

EID: 84855838599     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr449     Document Type: Article

References (20)

1. Dye C, Williams BG. Slow elimination of multidrug-resistant tuberculosis. Sci Transl Med 2009; 1: 3ra8.
2. Nuermberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-6.
3. Conde MB, Efron A, Loredo C et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-9.
4. Kaur P, Agarwal S, Datta S. Delineating bacteriostatic and bactericidal targets in mycobacteria using IPTG inducible antisense expression. PLoS One 2009; 4: e5923.
5. Charifson PS, Grillot A-L, Grossman TH et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 2008; 51: 5243-63.
6. Grossman TH, Bartels DJ, Mullin S et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 2007; 51: 657-66.
7. Glaser BT, Malerich JP, Duellman SJ et al. A high-throughput fluorescence polarization assay for inhibitors of gyrase B. J Biomol Screen 2011; 16: 230-8.
8. Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets 2007; 7: 159-68.
9. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41: 1004-9.
10. Hindler J. Antimicrobial susceptibility testing. In: Henry DI, ed. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology, 1992.
11. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
12. Cho SH, Warit S, Wan B et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 1380-5.
13. Van Helden PD, Victor TC, Warren RM et al. Isolation of DNA from Mycobacterium tuberculosis. In: Parish T, Stoker NG, eds. Mycobacterium tuberculosis protocols. New York: Humana Press, 2001; 19-30.
14. Scudiero DA, Shoemaker RH, Paull KD et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-33.
15. Maxwell A. DNA gyrase as a drug target. Trends Microbiol 1997; 5: 102-9.
16. Piton J, Petrella S, Delarue M et al. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 2010; 5: e12245.
17. Sassetti CM, Boyd DH, Rubin EJ. Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci USA 2001; 98: 12712-7.
18. Anderson VE, Gootz TD, Osheroff N. Topoisomerase IV catalysis and the mechanism of quinolone action. J Biol Chem 1998; 273: 17879-85.
19. Reddy TB, Riley R, Wymore F et al. TB database: an integrated platform for tuberculosis research. Nucleic Acids Res 2009; 37: D499-508.
20. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-7.